2. Washington, D.C. (March 15, 2011) — Demonstrating a steady and ongoing commitment to innovative R&D, America’s biopharmaceutical research companies invested a record $67.4 billion last year in the research and development of new medicines and vaccines – an increase of $1.5 billion from 2009, according to analyses by the Pharmaceutical Research and Manufacturers of America (PhRMA) and Burrill & Company. The third and final stage of clinical testing is designed to confirm the efficacy and safety of new drugs under development. Yet McKinsey research finds that, surprisingly, as many as four drugs in ten fail during this phase. To reduce the high number of late failures, pharmaceutical companies should reexamine their approach to the development of drugs and begin differentiating those in their pipelines by risk. McKensey Quarterly

3. MDA Market Opportunity (2010 Bio/Pharma R&D Expenditures)

4. MedifVu

5. MDA Deployment Model Q1Q2Q3Q4 Start Up 10 Disease Area 1 20 Disease Area 2 20 Disease Area 3 20 Review Board Training 30 Train The Trainer 20 20 Days /$40K40 Days /$80K60 Days /$120K 120 Days /$240KTotal Consulting DaaS Subscription $100K

6. MDA Business Plan December 2011 $1.5M Investment covers Application Development, Database population & first 6 Qtrs Operating cost $(000)